BioSante Pharmaceuticals announces receipt of two US patents directed to 2A/Furin technology

Mar 2 2010

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced the receipt of two US patents directed to its 2A/Furin technology for expressing proteins. The first issued US patent, US Pat. No., 7,632,059, covers methods for manufacturing recombinant antibodies. By incorporating our 2A/Furin technology into antibody-expression in viral vectors it is possible to rapidly generate stable, high producing antibody cell lines. The subsequent cell lines may greatly reduce the time and lower the cost of commercial antibody production. The second issued US patent, US Pat. No. 7,662,623 covers antibody expressing constructs containing the 2A/furin technology and builds on already issued patents covering vectors and methods for producing antibodies in vivo and in vitro. The two new patents expire in 2023.

“Our objective with this technology is to maximize its value to our stockholders in the shortest time possible. We are in discussion with interested parties who may seek a license to or acquisition of this exciting technology. The market for antibody products in 2008 was approximately $31 billion and growing.”

“We are pleased to receive these two new patents. These patents are the third and fourth issued patents in our patent estate covering our 2A/Furin technology and add patent protection for an additional manufacturing technology for quickly generating antibody producing cell lines. Additional patent applications are pending in the United States and outside the United States,” said Stephen M. Simes, president & CEO of BioSante. “Our objective with this technology is to maximize its value to our stockholders in the shortest time possible. We are in discussion with interested parties who may seek a license to or acquisition of this exciting technology. The market for antibody products in 2008 was approximately $31 billion and growing.”

The 2A/Furin technology rapidly generates cell lines that express levels of antibodies suitable for commercial production in a matter of weeks, compared to months for current techniques, which gives the potential to dramatically reduce the costs required to generate commercial antibodies. This technology allows for high-level, equimolar expression of two coding sequences using a single promoter that is applicable for generating expression vectors for in vivo gene therapy applications, pre-clinical target validation and lead identification as well as to rapidly generate high producer antibody cell lines that produce, in vitro, high levels of mature antibody without requiring any amplification currently employed in antibody expression systems.

SOURCE BioSante Pharmaceuticals, Inc.